stockportfolio.pro
Pulse Biosciences, Inc. (PLSE)
Healthcare · Medical Instruments & Supplies · NasdaqCM
Pulse Biosciences, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $1.42M | $700,000 | $0 | $0 | $350,000 |
| Gross profit | $-500,000 | $-800,000 | $-600,000 | $-600,000 | — | $-550,000 | $-11.24M | — | — | $-189,000 |
| Net income | $-9.52M | $-25.57M | $-37.55M | $-46.97M | $-49.85M | $-63.66M | $-58.51M | $-42.21M | $-53.59M | $-72.78M |
| Net margin | — | — | — | — | — | -4489.4% | -8357.9% | — | — | -20794.6% |
Source: Pulse Biosciences, Inc. SEC filings (10-K). 11 years of history available in the interactive view.
Explore 11 years of Pulse Biosciences, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track PLSE in your portfolio →
Pulse Biosciences, Inc. financial history by metric
About Pulse Biosciences, Inc.
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Pulse Biosciences, Inc. — frequently asked questions
What is Pulse Biosciences, Inc.'s revenue?
Pulse Biosciences, Inc. (PLSE) reported revenue of $350,000 for fiscal year 2025, according to its SEC filings.
Is Pulse Biosciences, Inc. profitable?
No — PLSE reported a net loss of $-72.78M in fiscal 2025.
What is PLSE's P/E ratio?
Pulse Biosciences, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Pulse Biosciences, Inc. have?
As of fiscal year 2025, PLSE carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Pulse Biosciences, Inc.'s gross margin?
PLSE's gross margin was -54.0% in fiscal 2025 — gross profit of $-189,000 on revenue of $350,000.
What is Pulse Biosciences, Inc.'s market cap?
Pulse Biosciences, Inc. (PLSE) has a market capitalization of about $1.84B, based on the latest data in our nightly-refreshed cache.
When does Pulse Biosciences, Inc.'s fiscal year end?
PLSE's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Pulse Biosciences, Inc.'s official SEC filings (10-K and 10-Q), covering 11 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.